Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $36 to $24.

June 28, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics but lowers the price target from $36 to $24.
The Overweight rating suggests a positive outlook, but the lowered price target indicates reduced expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100